食品科学 ›› 2026, Vol. 47 ›› Issue (18): 165-175.doi: 10.7506/spkx1002-6630-20260322-170

• 营养卫生 • 上一篇    

动物双歧杆菌乳亚种YRK-12缓解高尿酸血症的作用机制

牛一帆1,2,范城飞3,董胜胜4,韩丹丹4,郭金环4,王 然1,3,郝彦玲1,3,*   

  1. (1.河南工业大学粮油食品学院,河南 郑州 450001;2.中原食品实验室,河南 漯河 462300;3.中国农业大学营养与健康系,北京 100193;4.陕西益瑞康生物科技有限公司,陕西 咸阳 712000)
  • 发布日期:2026-09-29
  • 基金资助:
    “十四五”国家重点研发计划重点专项(2022YFF1100102)

Mechanism of Action of Bifidobacterium animalis subsp. lactis YRK-12 in Alleviating Hyperuricemia

NIU Yifan, FAN Chengfei, DONG Shengsheng, HAN Dandan, GUO Jinhuan, WANG Ran, HAO Yanling   

  1. (1. College of Food Science and Engineering, Henan University of Technology, Zhengzhou 450001, China; 2. Food Laboratory of Zhongyuan, Luohe 462300, China; 3. Department of Nutrition and Health, China Agricultural University, Beijing 100193, China; 4. Shaanxi Yiruikang Biotechnology Co. Ltd., Xianyang 712000, China)
  • Published:2026-09-29

摘要: 目的:为探究动物双歧杆菌乳亚种YRK-12缓解高尿酸血症(hyperuricemia,HUA)的潜在分子机制,本研究以肌苷、鸟苷和氧嗪酸钾联合灌胃构建HUA小鼠模型。方法:将所有小鼠随机分为对照组(CK)、HUA模型组(MOD)和动物双歧杆菌乳亚种YRK-12干预组(YRK-12)3 组,开展周期为21 d的灌胃实验。随后测定小鼠的血清生化指标、肝脏黄嘌呤氧化酶(xanthine oxidase,XOD)活性、组织病理切片、尿酸转运蛋白及炎症通路基因表达水平和肠道菌群的变化情况。结果:动物双歧杆菌乳亚种YRK-12干预显著降低了35.7%的血清尿酸水平,并改善了肾功能指标。YRK-12也显著降低了32.2%肝脏XOD活性及回肠XOD基因表达水平;显著下调了GLUT9、URAT1基因表达水平,下调幅度分别为44.8%和25.7%;并显著上调肾脏和结肠ABCG2基因表达水平,分别为22.0%和20.6%;同时可显著抑制炎症通路核因子-κB/NOD样受体热蛋白结构域相关蛋白3途径,使肾脏中NF-κB和NLRP3基因表达水平分别降低了40.4%和31.4%;此外,YRK-12增加了Actinomycetota菌门和产短链脂肪酸菌(如Alistipes putredinis、Suilimivivens aceti)的丰度,从而改善了肠道微生物失调。结论:动物双歧杆菌乳亚种YRK-12通过多途径达到缓解HUA的效果,包括调节尿酸合成和排泄、减轻组织的炎症反应和调节肠道菌群,为开发预防和缓解HUA的益生菌产品提供了理论依据与实验支撑。

关键词: 动物双歧杆菌乳亚种;高尿酸血症;黄嘌呤氧化酶;组织损伤;肠道菌群

Abstract: Objective: To explore the potential molecular mechanism by which Bifidobacterium animalis subsp. lactis YRK-12 alleviates hyperuricemia (HUA) induced by combined oral administration of inosine, guanosine and potassium oxonate in mice. Methods: All mice were randomly divided into three groups: control, HUA model (MOD), and B. animalis subsp. lactis YRK-12 intervention (YRK-12). The administration period lasted 21 days. Subsequently, serum biochemical indicators, liver xanthine oxidase (XOD) activity, histopathological sections, the expression of urate transporter genes and inflammatory genes, and changes in the intestinal flora were measured. Results: B. animalis subsp. lactis YRK-12 intervention significantly reduced serum uric acid levels by 35.7% and improved renal function indicators. YRK-12 significantly reduced liver XOD activity by 32.2% and decreased ileum XOD expression levels; the expression levels of glucose transporter 9 (GLUT9) and urate transporter 1 (URAT1) in the kidney were significantly down-regulated by 44.8% and 25.7%, respectively. The expression levels of ATP-binding cassette subfamily G member 2 (ABCG2) in the kidney and colon were significantly up-regulated by 22.0% and 20.6%, respectively. Meanwhile, YRK-12 significantly inhibited the nuclear factor kappa-B/NOD-like receptor family pyrin domain containing 3 (NF-κB/NLRP3) signaling pathway, reducing the expression levels of NF-κB and NLRP3 in the kidney by 40.4% and 31.4%, respectively. It also increased the abundance of Actinomycetota and short-chain fatty acid-producing bacteria (such as Alistipes putredinis and Suilimivivens aceti), thereby improving intestinal microbial dysbiosis. Conclusion: B. animalis subsp. lactis YRK-12 can alleviate HUA through multiple pathways, including regulating uric acid synthesis and excretion, reducing tissue inflammation, and modulating the intestinal flora. This finding provides a theoretical basis and experimental support for the development of probiotic products to prevent and alleviate HUA.

Key words: Bifidobacterium animalis subsp. lactis; hyperuricemia; xanthine oxidase; tissue damage; intestinal microflora

中图分类号: